Market Insights

Directed immobilization technology immobilizes target molecules or substances on specific sites or carriers via dedicated methods and materials. It is widely applied in biomedicine, materials science, and environmental monitoring. This technology can effectively improve detection efficiency, reduce workload and research costs, and has been widely adopted and studied as an efficient strategy in various scientific fields.

Targeted Protein Degradation (TPD) technology has rapidly evolved over the past two decades as a method to disrupt protein function. The aim of this technology is to selectively degrade specific proteins, thereby modulating cellular processes and signaling pathways.

Nanobodies are promising tools for targeted detection and clinical therapy. Current research on Helicobacter pylori (HP) targeting mainly focuses on peptides, scFv, yolk antibodies, and monoclonal antibodies. Although nanobodies have high affinity, good stability, low immunogenicity, small size, and easy modification, effective HP-targeted nanobody drugs have not been well developed.

Recently, Johnson & Johnson (JNJ) announced that its developed bispecific antibody, Rybrevant (amivantamab), has received full approval from the U.S. FDA for its use in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.

Winter is the peak season for acute cardiovascular and cerebrovascular events. Cold weather raises blood pressure and induces cerebral vasospasm, increasing the risk of stroke, myocardial infarction and sudden cardiac death. Research shows that every 1°C drop in temperature raises heart disease incidence by about 2%. Traditional treatments remain limited despite common approaches like fat reduction and vessel dilation.

Diabetes, referred to as 'Xiaoke syndrome' in traditional Chinese medicine in China, has been documented in classic Chinese medical texts such as the 'Huangdi Neijing' and 'Lingshu' as early as around 400 BC. It refers to type 2 diabetes mellitus (T2DM), characterized by symptoms such as polydipsia, polyphagia, polyuria, as well as emaciation, fatigue, and sweet urine.

Nanobodies (Nbs) are single-domain antibodies composed of variable heavy-chain domains (VHHs) derived from camelids. Their unique structure and superior properties have positioned them as a research hotspot in the global biopharmaceutical field.

Neurological diseases encompass a range of conditions that affect the normal functioning of the human nervous system, such as Alzheimer's disease, Parkinson's disease, and spinal cord injuries. These ailments significantly impact the quality of life and health of patients, causing profound suffering not only to those afflicted but also to their families and friends, casting enduring psychological shadows on all involved

Tumor. It's a name that still sends shivers down the spine worldwide. How to quickly detect, diagnose, and treat tumors has always been a major challenge in the medical field. With countless scientists and medical professionals continuously researching and discovering, nanobodies, as an emerging treatment strategy, have brought revolutionary changes to cancer treatment.

Since the outbreak of the COVID-19 pandemic in 2020, the biopharmaceutical industry has encountered numerous challenges, marking one of the most turbulent periods in its history. The emergence and global spread of the COVID-19 pandemic have accelerated innovation and research processes within the biopharmaceutical sector.